Health Care & Life Sciences » Biotechnology | GenSight Biologics

GenSight Biologics S.A. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
17,093.40
12,071.60
30,059.90
53,982.20
55,448.00
-
Total Accounts Receivable
1,120.30
1,712.00
3,858.50
3,358.20
4,242.00
-
Other Current Assets
42.30
483.70
1,194.90
574.10
754.00
-
Total Current Assets
18,256.00
14,267.30
35,113.20
57,914.50
60,444.00
-
Net Property, Plant & Equipment
325.30
277.80
861.00
858.20
889.00
-
Total Investments and Advances
31.30
31.40
110.90
103.20
327.00
-
Intangible Assets
259.00
240.00
225.10
203.60
185.00
-
Total Assets
18,871.60
14,816.50
36,310.30
59,079.50
61,845.00
-
Accounts Payable
1,374.40
1,909.20
5,192.70
1,734.10
2,225.00
Income Tax Payable
7.40
103.50
5.60
17.20
28.00
Other Current Liabilities
514.50
1,552.00
1,095.20
1,143.70
1,842.00
Total Current Liabilities
1,896.30
3,564.70
6,293.50
2,894.90
4,095.00
Provision for Risks & Charges
9.80
40.50
68.20
73.00
88.00
Total Liabilities
1,906.10
3,605.20
6,361.70
2,967.90
4,183.00
Common Equity (Total)
16,965.50
10,579.00
29,326.40
53,189.10
54,629.00
Total Shareholders' Equity
16,965.50
10,579.00
29,326.40
53,189.10
54,629.00
Total Equity
16,965.50
10,579.00
29,326.40
53,189.10
54,629.00
Liabilities & Shareholders' Equity
18,871.60
14,816.50
36,310.30
59,079.50
61,845.00
Non-Equity Reserves
-
632.30
622.20
2,922.40
3,033.00

About GenSight Biologics

View Profile
Address
74, rue du Faubourg Saint-Antoine
Paris Ile-de-France 75012
France
Employees -
Website http://www.gensight-biologics.com
Updated 07/08/2019
GenSight Biologics SA operates as a biopharmaceutical company, which develops novel therapies for mitochondrial and neurodegenerative diseases for central nervous system based on its proprietary platform technologies that combine gene therapy on mitochondrial targeting and optogenetics. It also provides ophthalmology services, which develops products to restore eyesight to patients suffering from retinal diseases. The company was founded by Bernard Jacques Alex Gilly, Botond Roska, Jean Benn, Luk H.